Skip to content
value.today

Athos Therapeutics, Inc.

🇺🇸 Los Angeles, California, USAPharmaceuticalsFounded 2019
Total raised
$28 M
2 rounds on record
Latest round
$8 M
Jan 2024
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Athos Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2024$8 MNo. 2$2 to $10 million

Athos Therapeutics, Inc.: Raise no. 2, Jan 2024

Investors in this round

30 investors had bought by the notice of Feb 6, 2024: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $35 M offered; $27 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allan J. Pantuck · Executive Officer, Director
  • Dimitrios Iliopoulos · Executive Officer, Director
  • Anthony J. Zingale · Director
  • Carl J. McKinzie · Director
  • Joel J. Cohen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dimitrios Iliopoulos, President. Source: SEC Form D, newest notice filed Feb 6, 2024. Read the notice at the SEC.

equitySEC
Sep 2021$20 MNo. 1$10 to $50 million

Athos Therapeutics, Inc.: Raise no. 1, Sep 2021

Investors in this round

103 investors had bought by the notice of Nov 17, 2021: 103 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Allan J. Pantuck · Executive Officer, Director
  • Dimitrios Iliopoulos · Executive Officer, Director
  • Carl J. McKinzie · Director
  • Joel J. Cohen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dimitrios Iliopoulos, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 17, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Athos Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).

    SEC Form D · Feb 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2024

That is all the official record says: Athos Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Athos Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 103 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Athos Therapeutics, Inc.
NameRoleNamed in
Allan J. PantuckExecutive officerFeb 2024
Dimitrios IliopoulosExecutive officerFeb 2024
Allan J. PantuckDirectorFeb 2024
Anthony J. ZingaleDirectorFeb 2024
Carl J. McKinzieDirectorFeb 2024
Dimitrios IliopoulosDirectorFeb 2024
Joel J. CohenDirectorFeb 2024